Home › Funds › Venrock Adviser, LLC › XFOR
Venrock Adviser, LLC position in XFOR
X4 PHARMACEUTICALS INC · Health Care
Venrock Adviser, LLC reported holding 7,644,072 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$22.2M, representing 1.08% of its reported portfolio and ranking #22 among its reported holdings. Venrock Adviser, LLC has disclosed XFOR holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's XFOR position evolved
Venrock Adviser, LLC first disclosed a stake in XFOR in Q1 2026 at 330,525 shares (US$1.4M). The position peaked in Q3 2026 at 7,644,072 shares, worth US$22.2M. Across 3 filings, Venrock Adviser, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 7,644,072 shares valued at US$22.2M — an increase of 5,709,819 shares quarter over quarter.. Notable position changes include a 485% increase in Q2 2026 (shares fell 38% over the following quarter), a 295% increase in Q3 2026 (shares fell 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 330.52K | $1.37M | New |
| Q2 2026 | 1.93M | $9.03M | Add |
| Q3 2026 | 7.64M | $22.17M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XFOR and 13F data
XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in XFOR — the largest reported positions include Empery Asset Management, LP (US$28.2M), Bain Capital Life Sciences Investors, LLC (US$23.1M), Saturn V Capital Management LP (US$21.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XFOR
- Empery Asset Management, LP 9.73M sh · $28.20M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 7.97M sh · $23.11M · Q3 2026
- Saturn V Capital Management LP 7.37M sh · $21.36M · Q3 2026
- PERCEPTIVE ADVISORS LLC 7.35M sh · $21.32M · Q3 2026
- Kalehua Capital Management LLC 3.72M sh · $10.80M · Q3 2026
- NEA Management Company, LLC 3.23M sh · $9.38M · Q3 2026
- Rosalind Advisors, Inc. 3.21M sh · $9.32M · Q3 2026
- Trails Edge Capital Partners, LP 2.57M sh · $7.46M · Q3 2026
- BVF INC/IL 1.58M sh · $4.57M · Q3 2026
- Samsara BioCapital, LLC 1.35M sh · $3.91M · Q3 2026
- Verdad Advisers, LP 323.17K sh · $937.18K · Q3 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held XFOR?
Venrock Adviser, LLC has disclosed XFOR holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Venrock Adviser, LLC's current position in XFOR?
As of Q3 2026, Venrock Adviser, LLC holds 7.64M shares of XFOR (X4 PHARMACEUTICALS INC), valued at $22.17M, representing 1.08% of its reported portfolio and ranking #22.
Has Venrock Adviser, LLC been buying or selling XFOR?
In the latest 13F filing (Q3 2026), Venrock Adviser, LLC increased its position in XFOR. The position peaked in Q3 2026 at 7.64M shares.
Which other funds hold XFOR?
Other major institutional holders of XFOR include Empery Asset Management, LP, Bain Capital Life Sciences Investors, LLC, Saturn V Capital Management LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.